Atherosclerosis vaccine - AVANT Immunotherapeutics

Drug Profile

Atherosclerosis vaccine - AVANT Immunotherapeutics

Alternative Names: CETi-1; CETP vaccine - AVANT; Cholesteryl ester transfer protein vaccine - AVANT

Latest Information Update: 18 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Antihyperlipidaemics; Vaccines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Low HDL cholesterol

Most Recent Events

  • 03 May 2007 AVANT is seeking partnerships for its cardiovascular programmes (http://www.avantimmune.com)
  • 03 May 2007 Discontinued - Phase-II for Atherosclerosis in USA (Injection)
  • 03 May 2007 Discontinued - Phase-II for Low HDL cholesterol in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top